Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside

Back connected June 1, Voyager Therapeutics Inc. (NASDAQ:VYGR) received FDA support for VY1706, a cistron therapy for Alzheimer's that targets extracellular and intracellular tau. The institution had antecedently submitted an Investigational New Drug (IND) application, and this caller clearance volition let Voyager to statesman VY1706 objective trials connected individuals with preliminary symptoms of Alzheimer's. Dosages are projected to commencement during the past 6 months of 2026.

Pressmaster/Shutterstock.com

The institution CEO, Alfred W. Sandrock, reflected favorably connected this improvement that followed a thorough preclinical process. He emphasized however reducing tau tin beryllium a important measurement successful curing Alzheimer's. Sandrock stated:

"The IND clearance for VY1706 is the archetypal for a tau-targeted cistron therapy and follows a broad preclinical programme demonstrating a compelling pharmacology and information profile. Recent third-party information proceed to suggest that tau is the adjacent captious people successful Alzheimer's disease, and that reducing tau accumulation holds promise. We presumption VY1706 arsenic starring the adjacent procreation of tau targeting treatments; it is designed to durably trim tau macromolecule levels successful cardinal encephalon regions pursuing a azygous IV administration."

The institution shared that siRNA is the halfway of VY1706 and targets MAPT mRNA to little extracellular and intracellular tau levels successful the brain. As a vectorized core, it is embedded into a TRACER AAV capsid that utilizes ALPL to nonstop siRNA towards the brain.

Voyager Therapeutics Inc. (NASDAQ:VYGR) is simply a biotechnology company. It is progressive successful quality genetics to cure neurological diseases. The merchandise pipeline offered by this institution includes VY1706, TRACER, ALPL-VYGR-NeuroShuttle, and VY7523. The institution besides offers a probe programme to cure Huntington's disease.

While we admit the imaginable of VYGR arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.